Despite inflation increasing the manufacturing cost for this medicine while reimbursement has plummeted to less than half, PBAC said 'No' to a price rise for this drug but to address patient concerns the company has extended a November delisting deadline by six months
This member-led organisation has appointed the first female CEO in its 115-year history, following a national recruitment drive
The shortest line yet between America's MFN policy and a life-saving drug not being PBS listed has been drawn, with a company decrying the PBAC's unwillingness to adapt
Nine pharmas hope to add new labels to their drugs in Australia in 2027 after the TGA accepted their applications for evaluation between June and July
Faced with growing challenges to listing some drugs on the PBS, Lilly has launched a platform to facilitate dispensing and delivery of medications to a patient's door at more affordable prices
Another impressive trial win for Summit Therapeutics' challenger to the world's biggest drug has been branded a good omen for Big Pharmas in the same space
There has a been a rush on senior leadership moves across industry with a string of departures, returns, company moves and internal promotions
Company details future mega revenue earners while also releasing topline results for its next star performer, which beat a rival Lilly drug in a head-to-head trial
The Federal Government's Intergenerational Report forecasts PBS spending will grow more slowly than health spending as a whole
Australia's medicines regulator has accepted an additional 10 Type A applications between June and July, with some pegged blockbusters making the list
The local giant has shored up isotope supply for its late-stage pipeline with the icing on the cake, acquiring a radiopharmaceutical on the cusp of winning FDA approval
Biosimilar and generic drugmakers have emerged as the top contenders to secure an October PBS listing, including one drug that could force a price cut for a $72 million-a-year blockbuster
Health Minister Mark Butler announces another two October listings, one of which will benefit more than 143,000 Australians from the start of next month
A new vaccine has been approved by the TGA for adults along with new versions of drugs sponsored by Celltrion Healthcare, Kyowa Kirin, and UCB.
Media reports of a spate of domestic violence homicides over the weekend included one accused's defence that he was affected by Ozempic.
Under an expanded deal, this company has snagged Australian rights to a new topical formulation of a well-known JAK inhibitor
Leaving after 24 years, this latest exit follows a string of CEO departures across Australia’s biotech sector
Medicinal cannabis patients in NSW will no longer have to choose between taking their medicine or driving after reforms abolish automatic license loss and heavy fines
In what's been described as the biggest industry transformation in 30 years, pharma is facing a 'commercialisation reset' on how it does business
A corporate and strategic communications advisory agency has buffed up its team with a former J&J and Novartis corporate affairs leader joining the ranks
Two months on from the PBAC's July meeting, just over 60 per cent of the submissions recommended have started progressing towards a PBS listing
A harried Government has announced politically urgent PBS funding for a drug to replace one that is being pulled from the Scheme in November
Transforming Medical Information into a strategic source of intelligence for pharmas by unlocking more value from every scientific interaction
